Track topics on Twitter Track topics that are important to you
The FDA approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. “Idhifa […]
The post FDA approves Idhifa for relapsed or refractory acute myeloid leukemia appeared first on CenterWatch News Online.
Original Article: FDA approves Idhifa for relapsed or refractory acute myeloid leukemiaNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...